Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Sterling Drug Will Get A Booster Shot


In Business This Week

STERLING DRUG WILL GET A BOOSTER SHOT

Eastman Kodak paid $5 billion for Sterling Drug in 1988, but the unit is still a 98-pound weakling in a land of pharmaceutical giants. To bulk up, Kodak plans to share future sales-and-development costs with a European drugmaker. On Jan. 9, it disclosed plans to form an alliance with France's Sanofi that would create U. S.- and French-based companies with $2.3 billion in combined sales and an annual $500 million development budget. Expected to be completed by Mar. 31, the deal would pool some operations while retaining two separately managed businesses, each to be called Sanofi Winthrop.

Sterling, which has few new drugs in its labs, would win forthcoming Sanofi hypertension and heart drugs and would give the French subsidiary of Elf Aquitaine access to Sterling's U. S. and European sales outlets.EDITED BY HARRIS COLLINGWOOD


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus